Table 2.
TXA2 summary in all 60 evaluable participants.
| TXA2 measurement | Arm AAspirin placebo + PPI(n = 20) | Arm BLow-dose aspirin + PPI(n = 20) | Arm CHigh-dose aspirin + PPI(n = 20) |
|---|---|---|---|
| Pre-treatment | |||
| Mean (S.D.) | 6800.7 (9307.0) | 4835.1 (5401.7) | 7602.9 (6724.6) |
| Median (range) | 2954.4 (104.8 to 33,277.1) | 2876.4 (144.5 to 20,813.6) | 5180.9 (219.5 to 19,871.5) |
| Post-treatment | |||
| Mean (S.D.) | 7111.0 (8286.7) | 142.4 (93.4) | 66.7 (24.0) |
| Median (range) | 4102.5 (179.0 to 30,121.6) | 117.5 (43.5 to 415.2) | 61.1 (31.5 to 119.7) |
| Absolute change | |||
| Mean (S.D.) | 310.3 (5469.6) | −4692.7 (5400.5) | −7536.2 (6722.2) |
| Median (range) | 211.7 (−10,078.9 to 16,905.9) | −2776.1 (−20,675.2 to 4.8) | −5071.3 (−19,813.9 to 168.8) |
| Within-arm signed rank p value | p = 0.765 | p < 0.001 | p < 0.001 |
| Wilcoxon rank sum p value | vs aspirin placebo | vs aspirin placebo | |
| p = 0.001 | p <0.001 | ||
| low-dose vs high-dose aspirin | |||
| p = 0.201 | |||
| Percent change | |||
| Mean (S.D.) | 182.4 (379.1) | −88.9 (23.2) | −96.3 (5.9) |
| Median (range) | −2.2 (−66.3 to 1343.1) | −96.4 (−99.3 to 3.3) | −98.8 (−99.7 to −76.9) |
| Within-arm signed rank p value | p = 0.179 | p < 0.001 | p < 0.001 |
| Wilcoxon rank sum p value | vs aspirin placebo | vs aspirin placebo | |
| p < 0.001 | p < 0.001 | ||
| Low dose vs high-dose aspirin | |||
| p = 0.015 | |||
Note: all values are expressed as picograms per milliliter.